Why the study?
To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel subcutaneous GLP-1R/GCGR dual agonist BI 456906 versus placebo in healthy volunteers and people with overweight or obesity.
Does the dual GLP-1R/GCGR agonist BI 456906 reduce body weight and demonstrate safety compared to placebo in healthy volunteers and individuals with overweight/obesity?
Population
24 males with BMI 20–<30 kg/m 2 and 125 adults with BMI 27–40 kg/m 2
Comparison
BI 456906 vs placebo
Design
Two phase I studies (single rising dose and multiple rising dose)
Follow-up
Up to 16 weeks
Authors
Loading...
Supports advancement of BI 456906 into later-phase trials; extends GLP-1R/GCGR dual agonism to a new candidate in overweight/obesity.
Does the dual GLP-1R/GCGR agonist BI 456906 reduce body weight and demonstrate safety compared to placebo in healthy volunteers and individuals with overweight/obesity?
The novel dual GLP-1R/GCGR agonist BI 456906 demonstrates substantial dose-dependent weight loss up to 13.8% at 16 weeks, though with notable gastrointestinal and cardiovascular adverse events leading to some discontinuations.
Jungnik et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: